Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.

About REPROCELL

Make an inquiry

REPROCELL Corporate News (8)

Reinnervate Ltd and Roslin Cellab to partner around 3D stem cell printing products and technologies

Prof. Stefan Przyborski to participate at the XCellR8 Human Primary Cell Culture course, 7 November 2013

Alvetex 3D cell culture scaffolds chosen by investigators at Massachusetts General Hospital for study of bone loss during space flight

Scottish SMEs Announce Collaboration with Universities, Industry and NHS in Establishment of a £20m Stratified Medicine Scotland Innovation Centre

3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement

3D cell culture firm Reinnervate announces the release of Alvetex®Scaffold 96 well plates for high throughput 3D cell-based assays

Medicyte GmbH and Reinnervate Ltd to collaborate on development of next generation predictive 3D cell toxicity assays

Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd

Reinnervate and Tecan to develop automated 3D cell culture solutions for improved cellular assays

Reinnervate Ltd and Roslin Cellab announce plans to collaborate

Reinnervate Ltd announce Kirkstall Ltd collaboration

Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®

Alvetex® voted one of most technologically significant new research products by R&D magazine

Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine

Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture

Reinnervate completes expansion into new purpose-built facility at NETPark

Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells

Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells

Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP)

Reinnervate secures £1.8 million of investment to support commercialisation of Alvetex

Subscribe to receive updates